WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Monday, December 26, 2016

San Diego Company’s Parkinson’s Drug Shows Promise For Alzheimer’s

Monday, December 26, 2016
A bottle containing the Parkinson's drug Nuplazid is seen in this undated photo.
A drug made by San Diego-based Acadia Pharmaceuticals gained approval earlier this yearto treat Parkinson's-related psychosis, a problem experienced by many patients with the disease. 
This week, the company reported new study results suggesting their drug may also be effective at warding off hallucinations and delusions in Alzheimer’s patients.
The FDA approved pimavanserin, sold under the brand name Nuplazid, in April as the first drug to treat Parkinson’s-related psychosis. The agency called the problem "profoundly disturbing and disabling" and estimated it could affect half of patients to varying degrees.
On Tuesday, Acadia detailed results from a new clinical trial showing the drug also reduced psychosis in Alzheimer’s patients, though longer-term benefits of the drug remained unclear.
Acadia reported that patients who took the drug for six weeks saw a 3.76 point improvement on a clinical scale measuring hallucinations and delusions. Patients who took a placebo improved by 1.93 points during the same period.
Acadia said reductions in psychosis carried on past the six-week mark, but when patients were studied again at 12 weeks, the drug "did not statistically separate from placebo."
In a press release, Acadia’s CEO Steve Davis said the results "provide solid evidence that pimavanserin can improve psychosis in another major neurological disorder." 
The company’s stock price rose 13.6 percent on Tuesday.
The National Institutes of Health estimates that one million Americans suffer from Parkinson’s disease, and more than five million have Alzheimer’s. According to research, about 50 percent of Alzheimer’s patients can experience psychotic symptoms.
http://www.kpbs.org/news/2016/dec/26/san-diego-companys-parkinsons-drug-shows-promise-a/

No comments:

Post a Comment